Core C Microbiology and Virology. For the past 31 years, the Microbiology and Virology Core hassupported the projects of this Program by creating and maintaining an extensive Infectious Diseases (ID)database. This database has been critical for projects that have Infectious Disease endpoints. Over theyears the function and services provided by the Core have expanded, mainly driven by the availability ofhighly sensitive and quantitative diagnostic capabilities, which made it imperative to have standardizeddefinitions and interpretations of diagnostic test results for the Programs. Therefore, all infection endpointsfor clinical trials or studies related to the aims of the projects are discussed with the Core director, the Coreprovides statistical support and data management for specific ID analyses related to the projects. State-of -the-art diagnostic capabilities are provided and continuous efforts are made to improve diagnosticcapabilities for pathogens relevant to hematopoietic cell transplant recipients. The Core also maintains aprospective sample collection to facilitate infection diagnosis using research diagnostic assays. In addition,the Core provides monitoring capabilities for immune reconstitution studies. Specifically, the Core providesthe following services:1. State-of-the-art diagnostic molecular capabilities for the detection of occult infections and pathogen quantitation. These assays will be applied in patients with idiopathic pneumonia syndrome and for optimizing BAL and tissue-based quantitative molecular diagnosis.2. Provision of data management and statistical services to Project and Core leaders.3. Data entry and quality control of the IDdatabases.4. Assistance to Project and Core leaders in defining ID endpoints, including assurance of appropriate use of ID database, and assistance in analysis of ID data.5. Maintaining a tissue sample repository (BAL and blood).6. Antigen preparation for T cell assays.Relevance to Public Health: This Core will assist Projects by applying new diagnostic tests for infectiousagents to samples from patients undergoing allogeneic hematopoietic cell transplantation and by makingaccurate and consistent diagnoses of infectious complications. The Core will store clinical samples, apply abattery of research diagnostic tests, establish infectious disease diagnoses, and correlate infections withtransplant outcomes. These efforts will not only aid this Program Project in achieving its goals, but will likelylead to a better understanding of infectious complications in other immunosuppressed patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-32
Application #
7226434
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (O5))
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2007-03-22
Budget End
2008-02-29
Support Year
32
Fiscal Year
2007
Total Cost
$237,188
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications